Insight on Pharmaceuticals

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

F. Hoffmann-La Roche Ltd: PharmaVitae Report

Analysis of Roche's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
06 Jun 2011 $2800
Buy
Report
Report

Genzyme Corporation: PharmaVitae Report

Analysis of Genzyme's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
06 May 2011 $2800
Buy
Report
Report

Pharmaceutical Key Trends 2011: Pharmaceutical Industry Infrastructure Overview

Overview of cost-cutting, M&A and R&D trends across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

Published By Datamonitor
31 Mar 2011 $2800
Buy
Report
Report

Pharmaceutical Key Trends 2011: Healthcare System and Drug Regulatory Overview

Analysis of healthcare expenditure, reforms, pricing and reimbursement and drug regulation across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

Published By Datamonitor
25 Mar 2011 $2800
Buy
Report
Report

Pharmaceutical Key Trends 2011: Biosimilar Market Overview

Comparative analysis of biosimilar drivers and resistors, key players, market access, pricing, and future launches across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

Published By Datamonitor
23 Feb 2011 $2800
Buy
Report
Report

Germany Pharmaceutical Market Overview – New pricing rules set to negatively impact drug sales both domestically and internationally

Overview of the German pharmaceutical market including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis and pharmaceutical company infrastructure analysis.

Published By Datamonitor
15 Dec 2010 $3600
Buy
Report
Report

Pharmaceutical Licensing and Alliances in the Asia-Pacific Region – Pharma enhances its focus on APAC markets

An overview of licensing and alliance trends in developed and emerging pharmaceutical markets in the Asia-Pacific region from Q3 2009 to Q2 2010, including discussion of the drivers of recent deals and analysis of key agreements.

Published By Datamonitor
19 Nov 2010 $2800
Buy
Case Studies
Case Studies

Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014

This case study looks at Teva's operations and the market in which it operates, Copaxone, Teva's best-selling drug, and M&A activity Teva has been involved in over recent years, and whether or not it has been successful.

Published By MarketLine
11 Apr 2014 $495
Buy
Case Studies
Case Studies

Orphan Drugs: Rescue from the patent cliff

Big Pharma has gone through some significant changes in recent years: many “blockbuster” drugs are losing their patents. In the orphan drugs market, where companies can charge high premiums for drugs which have little to no competition.

Published By MarketLine
03 Dec 2013 $495
Buy
Case Studies
Case Studies

Pfizer Inc: Re-entry to the OTC healthcare market

Pfizer exited the OTC healthcare market in 2006 with the sale of its Consumer Healthcare division. In 2009, Pfizer re-entered the market. This case study will examine Pfizer's growth, disposal of the OTC division, and the subsequent market re-entry.

Published By MarketLine
11 Apr 2013 $495
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

No help is available.